Stock Scorecard

Stock Summary for BeyondSpring Inc (BYSI) - $1.72 as of 11/20/2024 3:50:53 PM EST

Total Score

7 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for BYSI

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for BYSI

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for BYSI

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for BYSI

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for BYSI (10 out of 90)

Stock Price Rating (Max of 10) 2
Historical Stock Price Rating (Max of 10) 5
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 1
Price to Earnings (Max of 10) 0

Latest News for for BYSI

BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024 - BeyondSpring ( NASDAQ:BYSI ) , Merck & Co ( NYSE:MRK ) 9/16/2024 11:00:00 AM
BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024 9/16/2024 11:00:00 AM
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024 - BeyondSpring ( NASDAQ:BYSI ) 9/16/2024 11:00:00 AM
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024 9/16/2024 11:00:00 AM
SEED Therapeutics ( SEED ) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications 8/6/2024 11:00:00 AM
Molecular Glues Clinical Trial Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight 7/11/2024 9:31:00 PM
BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics - BeyondSpring ( NASDAQ:BYSI ) 5/3/2024 11:00:00 AM
BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results 4/29/2024 9:30:00 PM
BeyondSpring Files 2023 Annual Report on Form 20-F 4/29/2024 9:30:00 PM
BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer - BeyondSpring ( NASDAQ:BYSI ) 3/25/2024 11:00:00 AM

Financial Details for BYSI

Company Overview
Ticker BYSI
Company Name BeyondSpring Inc
Country USA
Description BeyondSpring Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology cancer therapies. The company is headquartered in New York, New York.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 6/30/2024
Next Earnings Date N/A

Stock Price History
Last Day Price 1.72
Price 4 Years Ago 12.20
Last Day Price Updated 11/20/2024 3:50:53 PM EST
Last Day Volume 20,808
Average Daily Volume 21,879
52-Week High 4.00
52-Week Low 0.78
Last Price to 52 Week Low 120.51%

Valuation Measures
Trailing PE N/A
Industry PE 22.60
Sector PE 40.32
5-Year Average PE -5.05
Free Cash Flow Ratio 8.19
Industry Free Cash Flow Ratio 12.03
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 1.82
Total Cash Per Share 0.21
Book Value Per Share Most Recent Quarter -0.75
Price to Book Ratio 5.38
Industry Price to Book Ratio 5.31
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 36.95
Industry Price to Sales Ratio Twelve Trailing Months 11.82
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings N/A
Analyst Strong Buy Ratings N/A

Share Statistics
Total Shares Outstanding 40,300,400
Market Capitalization 69,316,688
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 42.05%
Reported EPS 12 Trailing Months -0.40
Reported EPS Past Year -1.73
Reported EPS Prior Year -1.72
Net Income Twelve Trailing Months -17,774,999
Net Income Past Year -21,026,000
Net Income Prior Year -36,280,000
Quarterly Revenue Growth YOY 14.30%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months -7.42

Balance Sheet
Total Cash Most Recent Quarter 8,397,000
Total Cash Past Year 7,809,000
Total Cash Prior Year 34,396,000
Net Cash Position Most Recent Quarter 8,397,000
Net Cash Position Past Year 5,642,000
Long Term Debt Past Year 2,167,000
Long Term Debt Prior Year 2,167,000
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 0.00
Equity to Debt Ratio Most Recent Quarter 0.00
Total Stockholder Equity Past Year -26,805,000
Total Stockholder Equity Prior Year -5,979,000
Total Stockholder Equity Most Recent Quarter -30,185,000

Free Cash Flow
Free Cash Flow Twelve Trailing Months 0
Free Cash Flow Per Share Twelve Trailing Months 0.00
Free Cash Flow Past Year -16,574,000
Free Cash Flow Prior Year -27,498,000

Options
Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating None

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD -0.14
MACD Signal -0.08
20-Day Bollinger Lower Band 1.63
20-Day Bollinger Middle Band 2.09
20-Day Bollinger Upper Band 2.54
Beta 0.30
RSI 24.23
50-Day SMA 2.01
150-Day SMA 1.66
200-Day SMA 4.54

System
Modified 11/20/2024 8:26:41 PM EST